SCHEMBL1261992

SCHEMBL1261992

CC(CO)CNC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1261996 1.00
SCHEMBL1261990 1.00
SCHEMBL21359205 0.87 CYP2D6 (0.70)
SCHEMBL25192268 0.81 CYP2D6 (0.56)
SCHEMBL4578403 0.81 CYP2D6 (0.56)
SCHEMBL22273185 0.80
SCHEMBL12506706 0.80
SCHEMBL20688103 0.80
SCHEMBL22311455 0.80
SCHEMBL2332543 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112262129-B Triazacyclododecanesulfonamide (\"TCD\") based protein secretion inhibitors 科智生命科学公司 2024-05-14 CN disclosed
US-20230407285-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF DOGMA THERAPEUTICS, INC. 2023-12-21 US disclosed
WO-2023196556-A1 CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF CORBUS PHARMACEUTICALS, INC. (US) 2023-10-12 WO disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11603523-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2023-03-14 US disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20220220122-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2022-07-14 US disclosed
EP-3911640-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2021-11-24 EP disclosed
EP-3911648-A2 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2021-11-24 EP disclosed
EP-1863812-B1 DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT LG LIFE SCIENCES LTD (KR) 2010-07-14 EP disclosed
EP-1863812-A4 DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT LG LIFE SCIENCES LTD (KR) 2009-06-24 EP disclosed
US-20080188471-A1 Dipeptidyl Peptidase-IV Inhibiting Compounds, Method Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent LG LIFE SCIENCES, LTD. (KR) 2008-08-07 US disclosed
EP-1863812-A1 DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT LG Life Sciences Ltd. (KR) 2007-12-12 EP disclosed
WO-2006104356-A1 DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT LG LIFE SCIENCES, LTD. (KR) 2006-10-05 WO disclosed
US-6710203-B2 REACTING AQUEOUS AMMONIUM HYDROXIDE AND A CYCLIC CARBONATE TO OBTAIN HYDROXYALKYLCARBAMATE HUNTSMAN PETROCHEMICAL CORPORATION 2004-03-23 US disclosed
EP-1320519-A1 PREPARATION OF HYDROXYALKYLCARBAMATES FROM SIX-MEMBERED CYCLIC CARBONATES HUNTSMAN PETROCHEMICAL CORPORATION (US) 2003-06-25 EP disclosed
WO-2002026700-A1 PREPARATION OF HYDROXYALKYLCARBAMATES FROM SIX-MEMBERED CYCLIC CARBONATES HUNTSMAN PETROCHEMICAL CORPORATION (US) 2002-04-04 WO disclosed
US-20020040160-A1 Preparation of hydroxyalkylcarbamates from six-membered cyclic carbonates HUNTSMAN PETROCHEMICAL CORPORATION (N/K/A HUNTSMAN PETROCHEMICAL LLC) 2002-04-04 US disclosed
US-6262297-B1 DECYCLIZATION USING AMMONIA HUNTSMAN PETROCHEMICAL CORPORATION 2001-07-17 US disclosed